Abstracts tagged "Quality of care and vaccines"

Abstract Number: 385 • 2017 ACR/ARHP Annual Meeting
Reliable Implementation of a Hepatitis B Serology Screening and Vaccination Process for Immunocompromised Pediatric Rheumatology Patients
Emily A. Smitherman¹, Adam Furnier², Allen Watts¹, Sandra Kramer¹, Elizabeth Joy Baker¹, Dana MH Dykes³, Rebecca Brady⁴ and Jennifer L. Huggins⁵, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Vaccine-preventable infections, including reactivation of hepatitis B virus, are a leading cause of morbidity and mortality in immunocompromised patients. Guidelines recommend that all immunosuppressed…
Abstract Number: 849 • 2013 ACR/ARHP Annual Meeting
Reasons For Failure To Obtain Influenza and Pneumococcal Vaccines Among Immunosuppressed Individuals With Systemic Lupus Erythematosus
Erica F. Lawson¹, Laura Trupin², Emily von Scheven³, Edward H. Yelin² and Jinoos Yazdany², ¹Pediatrics, University of California, San Francisco, San Francisco, CA, ²Medicine, UC San Francisco, San Francisco, CA, ³Pediatrics, UC San Francisco, San Francisco, CA
Background/Purpose: Infection is the third-leading cause of death in individuals with systemic lupus erythematosus (SLE) in developed countries. Nearly half of those deaths are attributed…
Abstract Number: 2062 • 2012 ACR/ARHP Annual Meeting
Increasing Pneumococcal Vaccination for Immunosuppressed Patients: A Cluster Quality Improvement Trial
Sonali Desai¹, Lara Szent-gyorgyi², Alexander Turchin³, Bing Lu⁴, Anna A. Bogdanova², Michael Weinblatt⁵, Jonathan S. Coblyn⁶, Jeffrey O. Greenberg², Allen Kachalia² and Daniel H. Solomon⁷, ¹Medicine/ Rheumatology, Boston, MA, ²Medicine, Boston, MA, ³Endocrinology, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Increasing Pneumococcal Vaccination for Immunosuppressed Patients: A Cluster Quality Improvement TrialBackground/Purpose: It is important for patients on immunosuppressive medications to receive pneumococcal vaccination. Prior…
Abstract Number: 2049 • 2012 ACR/ARHP Annual Meeting
Improving Pneumococcal Vaccination and Documentation for Immunosuppressed Patients At a University-Based Rheumatology Clinic
Christine Peoples¹, Rohit Aggarwal¹, Heena Sheth², Aarat Patel³, Daniel Lupash⁴, Christine McBurney¹, Ashima Malik¹, Swati Modi¹, Ximena D. Ruiz⁵ and Douglas W. Lienesch¹, ¹Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Adult/Pediatric Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine/Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Centers for Disease Control and Prevention Guidelines recommend that all immunosuppressed patients receive the pneumococcal vaccine. The American College of Rheumatology Task Force Panel…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].